176 related articles for article (PubMed ID: 20863994)
1. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.
Lin YF; Chen YM; Hung KY; Chu TS; Kan WC; Huang CY; Lin SL; Kao TW; Huang JW; Chiang WC; Yen CJ; Tsai TJ; Wu KD; Wu MS
J Formos Med Assoc; 2010 Sep; 109(9):663-72. PubMed ID: 20863994
[TBL] [Abstract][Full Text] [Related]
2. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
4. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
5. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.
Hervás JG; Prados D; Cerezo S
Kidney Int Suppl; 2003 Jun; (85):S69-72. PubMed ID: 12753270
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.
de Francisco AL; Leidig M; Covic AC; Ketteler M; Benedyk-Lorens E; Mircescu GM; Scholz C; Ponce P; Passlick-Deetjen J
Nephrol Dial Transplant; 2010 Nov; 25(11):3707-17. PubMed ID: 20530499
[TBL] [Abstract][Full Text] [Related]
9. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
10. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.
Covic A; Passlick-Deetjen J; Kroczak M; Büschges-Seraphin B; Ghenu A; Ponce P; Marzell B; de Francisco AL
Nephrol Dial Transplant; 2013 Sep; 28(9):2383-92. PubMed ID: 23787550
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.
Chen JB; Chiang SS; Chen HC; Obayashi S; Nagasawa M; Hexham JM; Balfour A; Junge G; Akiba T; Fukagawa M
Nephrology (Carlton); 2011 Nov; 16(8):743-50. PubMed ID: 21854503
[TBL] [Abstract][Full Text] [Related]
13. Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study.
Barreto DV; Barreto Fde C; de Carvalho AB; Cuppari L; Draibe SA; Dalboni MA; Moyses RM; Neves KR; Jorgetti V; Miname M; Santos RD; Canziani ME
Nephron Clin Pract; 2008; 110(4):c273-83. PubMed ID: 19001830
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).
Qunibi WY; Hootkins RE; McDowell LL; Meyer MS; Simon M; Garza RO; Pelham RW; Cleveland MV; Muenz LR; He DY; Nolan CR
Kidney Int; 2004 May; 65(5):1914-26. PubMed ID: 15086935
[TBL] [Abstract][Full Text] [Related]
15. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
[TBL] [Abstract][Full Text] [Related]
16. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
17. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.
Ferreira A; Frazão JM; Monier-Faugere MC; Gil C; Galvao J; Oliveira C; Baldaia J; Rodrigues I; Santos C; Ribeiro S; Hoenger RM; Duggal A; Malluche HH;
J Am Soc Nephrol; 2008 Feb; 19(2):405-12. PubMed ID: 18199805
[TBL] [Abstract][Full Text] [Related]
18. Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.
Furukawa K; Ikawa T; Yokoi S; Yokouchi S; Kato K; Ueno M; Takahashi J
Ther Apher Dial; 2014 Jun; 18 Suppl 2():2-7. PubMed ID: 24975888
[TBL] [Abstract][Full Text] [Related]
19. Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels.
Iwata Y; Wada T; Yokoyama H; Toyama T; Kitajima S; Okumura T; Hara A; Yamahana J; Nakaya I; Kobayashi M; Kitagawa K; Kokubo S; Yoshimoto K; Shimizu K; Sakai N; Furuichi K; Koshino Y; Takeda S; Takasawa K; Ohta S; Takaeda M; Takaeda C; Kaneko S
Intern Med; 2007; 46(8):447-52. PubMed ID: 17443033
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
